GREGORY JULIA P 4

What Happened

• Julia P. Gregory, a director of Nurix Therapeutics, was granted an award of 31,250 derivative shares (stock option award) on 2026-05-15. The filing reports the acquisition price as $0.00, so no cash was paid at grant; the reported value at issuance is $0.

Key Details

• Transaction date: 2026-05-15; Reported price: $0.00 per share (derivative award).
• Quantity: 31,250 shares (derivative/stock option).
• Shares owned after the transaction: not specified in this filing.
• Footnote: The stock option vests 100% on the earlier of the next annual meeting of stockholders or May 15, 2027, subject to Gregory's continued service on the vesting date.
• Filing timeliness: Reported on 2026-05-15 (same day), indicating a timely Form 4.

Context

• This is a compensation grant (derivative stock option) rather than an open-market purchase or sale. The award vests in the future (by 5/15/2027 or sooner if the annual meeting occurs), so there is no immediate exercise or sale reported. Such awards are common for directors as part of compensation and do not, by themselves, indicate a buy or sell signal.